Health Condition 1: N970- Female infertility associated withanovulation
Conditions
Interventions
Intervention1: T.EGRICH and Placebo injection: T.EGRICH one tablet twice daily for a period of 3 months
Placebo injection 2 doses on Day 18 of menstrual cycle for consecutive 2 months
Control Interv
Sponsors
DrAbinaya
Eligibility
Inclusion criteria
Inclusion criteria: Presence of factors indicating compromised oocyte quality (advanced maternal age or previous IVF failures). Subjects with prior history of poor oocyte quality in terms of maturity on retrieval. Subjects who couldn’t meet the benchmark blastocyst conversion rate Female subjects who are willing to commit the study restrictions.
Exclusion criteria
Exclusion criteria: Subjects with endometriosis involving uterus, ovaries, bladder, fallopian tubes, pelvis or deeply infiltrating endometriosis. Subjects with diagnosis of HIV, HCV, HBV, VDRL and other sexually transmitted diseases. Known allergy or hypersensitivity to any components of Egrich tablets. History of significant medical conditions affecting fertility or pregnancy outcome. Use of medications known to impact fertility or oocyte quality within the past three months. Male factor such as SOAT (total count less than 1 million per ml)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Improvement in oocyte quality, measured by the number of competent metaphase II (MII) oocytes retrieved after IVF. Timepoint: Three months | — |
Secondary
| Measure | Time frame |
|---|---|
| Fertilization rate. Embryo quality (morphological scoring of embryos). Clinical pregnancy rate (confirmation via ultrasound of fetal heartbeat at 6–8 weeks post-transfer). Incidence of any adverse events during treatment. Timepoint: 3 months | — |
Countries
India
Contacts
Public ContactAbinaya Durasisingam
Department of Reproductive medicine and Endocrinology
Outcome results
None listed